Ion channels and transporters in the development of drug resistance in cancer cells

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 369, Issue 1638, 2014, Pages

  Hoffmann, Else K ^a   Lambe, Ian H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Apoptosis; Cancer; Drug resistance; Ion channels in cancer; Tumour proliferation

Indexed keywords

APOPTOSIS; CANCER; CYTOLOGY; DEVELOPMENTAL BIOLOGY; DRUG RESISTANCE; PATHOLOGY; PROTEIN; TUMOR;

ION CHANNEL;

APOPTOSIS; BIOLOGICAL MODEL; DRUG RESISTANCE; GENE EXPRESSION REGULATION; HUMAN; ION CHANNELS IN CANCER; ION TRANSPORT; METABOLISM; MULTIDRUG RESISTANCE; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; TUMOR GROWTH;

APOPTOSIS; CANCER; DRUG RESISTANCE; ION CHANNELS IN CANCER; TUMOUR PROLIFERATION;

APOPTOSIS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ION CHANNELS; ION TRANSPORT; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 84893464588     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2013.0109     Document Type: Review

References (84)

1. Krishna R, Mayer LD. 2000 Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11, 265-283. (doi:10.1016/S0928-0987(00)00114-7)
2. Lothstein L, Israel M, Sweatman TW. 2001 Anthracycline drug targeting: cytoplasmic versus nuclear-a fork in the road. Drug Resist. Update 4, 169-177. (doi:10.1054/drup.2001.0201)
3. Stavrovskaya AA. 2000 Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc). 65, 95-106.
4. El MG, Le TC, Batty GN, Faivre S, Raymond E. 2009 Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat Rev. 35, 167-174. (doi:10.1016/j.ctrv.2008.10.002)
5. Tamburrino A, Piro G, Carbone C, Tortora G, Melisi D. 2013 Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol. 4, 56. (doi:10.3389/fphar.2013.00056)
6. Giacomini KM et al. 2010 Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-236. (doi:10.1038/nrd3028)
7. Litman T, Druley TE, Stein WD, Bates SE. 2001 From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol. Life Sci. 58, 931-959. (doi:10.1007/PL00000912)
8. Breier A, Gibalova L, Seres M, Barancik M, Sulova Z. 2013 New insight into p-glycoprotein as a drug target. Anticancer Agents Med. Chem. 13, 159-170. (doi:10.2174/1871520138 04487380)
9. Dmitriev OY. 2011 Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B. Biochem. Cell Biol. 89, 138-147. (doi:10.1139/O10-150)
10. Howell SB, Safaei R, Larson CA, Sailor MJ. 2010 Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol. Pharmacol. 77, 887-894. (doi:10.1124/mol. 109.063172)
11. Kalayda GV, Wagner CH, Buss I, Reedijk J, Jaehde U. 2008 Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer 8, 175. (doi:10.1186/1471-2407-8-175)
12. Lehen'kyi V, Shapovalov G, Skryma R, Prevarskaya N. 2011 Ion channnels and transporters in cancer. 5. Ion channels in control of cancer and cell apoptosis 11. Am. J. Physiol. Cell Physiol. 301, C1281-C1289. (doi:10.1152/ajpcell.00249.2011)
13. Lang F, Hoffmann EK. 2012 Role of ion transport in control of apoptotic cell death. Compr. Physiol. 2, 2037-2061.
14. Bortner CD, Cidlowski JA. 1998 A necessary role for cell shrinkage in apoptosis. Biochem. Pharmacol. 56, 1549-1559. (doi:10.1016/S0006-2952(98)00225-1)
15. Lang F, Foller M, Lang K, Lang P, Ritter M, Vereninov A, Szabo I, Huber SM, Gulbins E. 2007 Cell volume regulatory ion channels in cell proliferation and cell death. Methods Enzymol. 428, 209-225. (doi:10.1016/S0074-7696(08)62498-5)
16. Okada Y, Maeno E. 2001 Apoptosis, cell volume regulation and volume-regulatory chloride channels. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 130, 377-383. (doi:10.1016/S1095-6433(01)00424-X)
17. Okada Y, Maeno E, Shimizu T, Dezaki K, Wang J, Morishima S. 2001 Receptor-mediated control of regulatory volume decrease (RVD) and apoptotic volume decrease (AVD). J. Physiol. 532, 3-16. (doi:10.1111/j.1469-7793.2001.0003g.x)
18. Okada Y. 2004 Ion channels and transporters involved in cell volume regulation and sensor mechanisms. Cell Biochem. Biophys. 41, 233-258. (doi:10.1385/CBB:41:2:233)
19. Poulsen KA, Andersen EC, Hansen CF, Klausen TK, Hougaard C, Lambert IH, Hoffmann EK. 2010 Deregulation of apoptotic volume decrease and ionic movements in multidrug-resistant tumor cells: role of chloride channels. Am. J. Physiol. Cell Physiol. 298, C14-C25. (doi:10.1152/ajpcell.00654.2008)
20. Prevarskaya N, Skryma R, Shuba Y. 2010 Ion channels and the hallmarks of cancer 7. Trends Mol. Med. 16, 107-121. (doi:10.1016/j.molmed.2010. 01.005)
21. - channel is involved in cisplatin resistance of cancer cells. J. Cell Physiol. 211, 513-521. (doi:10.1002/jcp.20961)
22. Min XJ, Li H, Hou SC, He W, Liu J, Hu B, Wang J. 2011 Dysfunction of volume-sensitive chloride channels contributes to cisplatin resistance in human lung adenocarcinoma cells 1. Exp. Biol. Med. (Maywood). 236, 483-491. (doi:10.1258/ebm. 2011.010297)
23. Hoffmann EK, Dunham PB. 1995 Membrane mechanisms and intracellular signalling in cell volume regulation. Int. Rev. Cytol. 161, 173-262.
24. Hoffmann EK, Lambert IH, Pedersen SF. 2009 Physiology of cell volume regulation in vertebrates. Physiol. Rev. 89, 193-277. (doi:10.1152/physrev. 00037.2007)
25. Maeno E, Takahashi N, Okada Y. 2006 Dysfunction of regulatory volume increase is a key component of apoptosis. FEBS Lett. 580, 6513-6517. (doi:10.1016/j.febslet.2006.10.074)
26. Numata T, Sato K, Okada Y, Wehner F. 2008 Hypertonicity-induced cation channels rescue cells from staurosporine-elicited apoptosis. Apoptosis 13, 895-903. (doi:10.1007/s10495-008-0220-y)
27. Friis MB, Friborg C, Schneider L, Nielsen MB, Lambert IH, Christensen ST, Hoffmann EK. 2005 Cell shrinkage as a signal to apoptosis in NIH3T3 fibroblasts. J. Physiol. 567(2), 427-443. (doi:10.1113/jphysiol.2005.087130)
28. Bortner CD, Scoltock AB, Sifre MI, Cidlowski JA. 2012 Osmotic stress resistance imparts acquired antiapoptotic mechanisms in lymphocytes 1. J. Biol. Chem. 287, 6284-6295. (doi:10.1074/jbc. M111.293001)
29. Reinehr R, Haussinger D. 2007 Hyperosmotic activation of the CD95 system. Methods Enzymol. 428, 145-160. (doi:10.1016/S0076-6879(07)28008-5)
30. Nielsen MB, Christensen ST, Hoffmann EK. 2008 Effects of osmotic stress on the activity of MAPKs and PDGFR-beta-mediated signal transduction in NIH-3T3 fibroblasts. Am. J. Physiol. Cell Physiol. 294, C1046-C1055. (doi:10.1152/ajpcell.00134.2007)
31. Chen KG, Sikic BI. 2012 Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin. Cancer Res. 18, 1863-1869. (doi:10.1158/1078-0432.CCR-11-1590)
32. - transport pathways in Ehrlich ascites tumor cells. J. Membr. Biol. 91, 227-244. (doi:10.1007/BF01868816)
33. Panayiotidis MI, Franco R, Bortner CD, Cidlowski JA. 2010 Ouabain-induced perturbations in intracellular ionic homeostasis regulate death receptor-mediated apoptosis. Apoptosis 15, 834-849. (doi:10.1007/s10495-010-0494-8)
34. Litman T, Pedersen SF, Kramhoft B, Skovsgaard T, Hoffmann EK. 1998 pH regulation in sensitive and multidrug resistant Ehrlich ascites tumor cells. Cell Physiol. Biochem. 8, 138-150. (doi:10.1159/000016277)
35. Gollapudi S, McDonald T, Gardner P, Kang N, Gupta S. 1992 Abnormal chloride conductance in multidrug resistant HL60/AR cells. Cancer Lett. 66, 83-89. (doi:10.1016/0304-3835(92)90284-3)
36. Kunzelmann K, Slotki IN, Klein P, Koslowsky T, Ausiello DA, Greger R, Cabantchik ZI. 1994 Effects of P-glycoprotein expression on cyclic AMP and volume-activated ion fluxes and conductances in HT-29 colon adenocarcinoma cells. J. Cell Physiol. 161, 393-406. (doi:10.1002/jcp.1041610302)
37. + channels and volumeregulated anion channels in multidrug-resistant small cell lung cancer cells. Cancer Res. 53, 4156-4160.
38. 2+activated anion currents in Ehrlich lettre ascites cells 7. J. Cell Physiol. 210, 831-842. (doi:10.1002/jcp.20918)
39. Dupere-Minier G, Desharnais P, Bernier J. 2010 Involvement of tyrosine phosphatase CD45 in apoptosis. Apoptosis 15, 1-13. (doi:10.1007/s10495-009-0413-z)
40. Heimlich G, Cidlowski JA. 2006 Selective role of intracellular chloride in the regulation of the intrinsic but not extrinsic pathway of apoptosis in Jurkat T-cells. J. Biol. Chem. 281, 2232-2241. (doi:10.1074/jbc.M507367200)
41. + channels: an essential pathway in programmed cell death. Am. J. Physiol. Lung Cell Mol. Physiol. 286, L49-L67. (doi:10.1152/ajplung.00041.2003)
42. Yu SP. 2003 Regulation and critical role of potassium homeostasis in apoptosis. Prog. Neurobiol. 70, 363-386. (doi:10.1016/S0301-0082(03)00090-X)
43. Liang F, Schulte BA, Qu C, Hu W, Shen Z. 2005 Inhibition of the calcium-and voltage-dependent big conductance potassium channel ameliorates cisplatin-induced apoptosis in spiral ligament fibrocytes of the cochlea. Neuroscience 135, 263-271. (doi:10.1016/j.neuroscience.2005.05.055)
44. Yu SP et al. 1997 Mediation of neuronal apoptosis by enhancement of outward potassium current. Science 278, 114-117. (doi:10.1126/science.278. 5335.114)
45. + channel function 203. Proc. Natl Acad. Sci. USA 100, 7803-7807. (doi:10.1073/pnas. 1232448100)
46. Meuth SG, Herrmann AM, Ip CW, Kanyshkova T, Bittner S, Weishaupt A, Budde T, Wiendl H. 2008 The two-pore domain potassium channel TASK3 functionally impacts glioma cell death 75. J. Neurooncol. 87, 263-270. (doi:10.1007/s11060-008-9517-5)
47. + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth 125. Cancer Cell. 11, 37-51. (doi:10.1016/j.ccr. 2006.10.020)
48. Han Y, Shi Y, Han Z, Sun L, Fan D. 2007 Detection of potassium currents and regulation of multidrug resistance by potassium channels in human gastric cancer cells 39. Cell Biol. Int. 31, 741-747. (doi:10.1016/j.cellbi.2007.01.008)
49. Lai W, Liu L, Zeng Y, Wu H, Xu H, Chen S, Chu Z. 2013 KCNN4 channels participate in the EMT induced by PRL-3 in colorectal cancer. Med. Oncol. 30, 566. (doi:10.1007/s12032-013-0566-z)
50. Beilke S, Oswald F, Genze F, Wirth T, Adler G, Wagner M. 2010 The zinc-finger protein KCMF1 is overexpressed during pancreatic cancer development and downregulation of KCMF1 inhibits pancreatic cancer development in mice. Oncogene 29, 4058-4067. (doi:10.1038/onc.2010.156)
51. Jang JH. 2004 FIGC, a novel FGF-induced ubiquitinprotein ligase in gastric cancers. FEBS Lett. 578, 21-25. (doi:10.1016/j.febslet.2004.10.071)
52. Kreppel M, Aryee DN, Schaefer KL, Amann G, Kofler R, Poremba C, Kovar H. 2006 Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells. Oncogene 25, 2795-2800. (doi:10.1038/sj. onc.1209300)
53. Dubois C, Vanden Abeele F, Prevarskaya N. 2013 Targeting apoptosis by the remodelling of calciumtransporting proteins in cancerogenesis. FEBS J. 280, 5500-5510. (doi:10.1111/febs.12246)
54. Orrenius S, Zhivotovsky B, Nicotera P. 2003 Regulation of cell death: the calcium-apoptosis link. Nat. Rev. Mol. Cell Biol. 4, 552-565. (doi:10.1038/nrm1150)
55. 2+ homeostasis and store-operated channels in prostate cancer cells 27. Cancer Cell. 1, 169-179. (doi:10.1016/S1535-6108(02)00034-X)
56. 2+ homeostasis and apoptotic resistance of neuroendocrinedifferentiated prostate cancer cells 8. Cell Death Differ. 11, 321-330. (doi:10.1038/sj.cdd.4401375)
57. Flourakis M et al. 2010 Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells 2. Cell Death Dis. 1, e75. (doi:10.1038/cddis.2010.52)
58. Faouzi M, Hague F, Potier M, Ahidouch A, Sevestre H, Ouadid-Ahidouch H. 2011 Down-regulation of Orai3 arrests cell-cycle progression and induces apoptosis in breast cancer cells but not in normal breast epithelial cells. J. Cell Physiol. 226, 542-551. (doi:10.1002/jcp.22363)
59. Ohkubo T, Yamazaki J. 2012 T-type voltageactivated calcium channel Cav3.1, but not Cav3.2, is involved in the inhibition of proliferation and apoptosis in MCF-7 human breast cancer cells. Int. J. Oncol. 41, 267-275.
60. +-ATPase please stand up? Acta Physiol. (Oxf). 187, 205-215. (doi:10.1111/j.1748-1716.2006.01562.x)
61. Han X, Yue J, Chesney RW. 2009 Functional TauT protects against acute kidney injury. J. Am. Soc. Nephrol. 20, 1323-1332. (doi:10.1681/ASN. 2008050465)
62. Tastesen HS, Holm JB, Moller J, Poulsen KA, Moller C, Sturup S, Hoffmann EK, Lambert IH. 2010 Pinpointing differences in cisplatin-induced apoptosis in adherent and non-adherent cancer cells. Cell Physiol. Biochem. 26, 809-820. (doi:10.1159/000323990)
63. Heller-Stilb B, van RC, Rascher K, Hartwig HG, Huth A, Seeliger MW, Warskulat U, Häussinger D. 2002 Disruption of the taurine transporter gene (taut) leads to retinal degeneration in mice. FASEB J. 16, 231-233.
64. Warskulat U, Borsch E, Reinehr R, Heller-Stilb B, Roth C, Witt M, Häussinger D. 2007 Taurine deficiency and apoptosis: findings from the taurine transporter knockout mouse. Arch. Biochem. Biophys. 462, 202-209. (doi:10.1016/j.abb. 2007.03.022)
65. - cotransporter isoform 1 accelerates temozolomidemediated apoptosis in glioblastoma cancer cells. Cell Physiol. Biochem. 30, 33-48. (doi:10.1159/000339047)
66. + exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin. Cancer Res. 9, 2366-2373.
67. Lauritzen G, Jensen MB, Boedtkjer E, Dybboe R, Aalkjaer C, Nylandsted J, Pedersen SF. 2010 NBCn1 and NHE1 expression and activity in DeltaNErbB2 receptor-expressing MCF-7 breast cancer cells: contributions to pHi regulation and chemotherapy resistance. Exp. Cell Res. 316, 2538-2553. (doi:10.1016/j.yexcr. 2010.06.005)
68. + exchanger. Cancer Lett. 308, 81-90. (doi:10.1016/j.canlet.2011.04.016)
69. Stock C, Mueller M, Kraehling H, Mally S, Noel J, Eder C, Schwab A. 2007 pH nanoenvironment at the surface of single melanoma cells. Cell Physiol. Biochem. 20, 679-686. (doi:10.1159/000107550)
70. Tredan O, Galmarini CM, Patel K, Tannock IF. 2007 Drug resistance and the solid tumor microenvironment. J. Natl Cancer Inst. 99, 1441-1454. (doi:10.1093/jnci/djm135)
71. 2+ pumps: structural diversity as the basis for functional versatility. Biochem. Soc. Trans. 35, 919-922. (doi:10.1042/BST0350919)
72. VanHouten J, Sullivan C, Bazinet C, Ryoo T, Camp R, Rimm DL, Chung G, Wysolmerski J. 2010 PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer. Proc. Natl Acad. Sci. USA 107, 11 405-11 410. (doi:10.1073/pnas.0911186107)
73. Baggott RR et al. 2012 Disruption of the interaction between PMCA2 and calcineurin triggers apoptosis and enhances paclitaxel-induced cytotoxicity in breast cancer cells. Carcinogenesis 33, 2362-2368. (doi:10.1093/carcin/bgs282)
74. Li M, Xiong ZG. 2011 Ion channels as targets for cancer therapy. Int. J. Physiol. Pathophysiol. Pharmacol. 3, 156-166.
75. Felipe A, Vicente R, Villalonga N, Roura-Ferrer M, Martinez-Marmol R, Sole L, Ferreres JC, Condom E. 2006 Potassium channels: new targets in cancer therapy 67. Cancer Detect Prev. 30, 375-385. (doi:10.1016/j.cdp.2006.06.002)
76. Duvvuri U et al. 2012 TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression 7. Cancer Res. 72, 3270-3281. (doi:10.1158/0008-5472.CAN-12-0475-T)
77. Kashyap MK et al. 2009 Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers. Cancer Biol. Ther. 8, 36-46. (doi:10.4161/cbt.8. 1.7090)
78. - channel ANO1/TMEM16A expression suppresses tumor growth and invasiveness in human prostate carcinoma. Cancer Lett. 326, 41-51. (doi:10.1016/j.canlet. 2012.07.015)
79. Stanich JE, Gibbons SJ, Eisenman ST, Bardsley MR, Rock JR, Harfe BD, Ordog T, Farrugia G. 2011 Ano1 as a regulator of proliferation. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G1044-G1051. (doi:10.1152/ajpgi.00196.2011)
80. Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S, Becchetti A. 2009 Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr. Med. Chem. 16, 66-93. (doi:10.2174/092986709787002835)
81. 2+ activation. J. Gen. Physiol. 141, 585-600. (doi:10.1085/jgp.201210861)
82. - channel. Am. J. Physiol. Cell Physiol. 304, C748-C759. (doi:10.1152/ajpcell.00228.2012)
83. Suzuki J, Umeda M, Sims PJ, Nagata S. 2010 Calciumdependent phospholipid scrambling by TMEM16F. Nature 468, 834-838. (doi:10.1038/nature09583)
84. - current and ClC-3 expression in human prostate cancer epithelial cells. Cancer Res. 64, 4841-4848. (doi:10.1158/0008-5472.CAN-03-3223)